Dr. Reddys Labs (RDY) Reports Q4 EPS of $0.49
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Dr. Reddy’s Q4 & FY15 Financial Results
May 12, 2015 7:21 AM EDT
Q4 FY15 Revenues at Rs. 38.7 billion
(YoY growth of 11%)
Q4 FY15 EBITDA at Rs. 8.1 billion
(21% of revenues)
FY15 Revenues at Rs. 148.2 billion
(YoY growth of 12%)
FY15 EBITDA at Rs. 36.2 billion
(24% of revenues)
HYDERABAD, India--(BUSINESS WIRE)-- Dr. Reddys Laboratories Ltd. (NYSE: RDY)Â (BSE: 500124)Â (NSE: DRREDDY) today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2015 under International Financial Reporting Standards (IFRS).
FY15: Key... More
